Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F22%3A10448753" target="_blank" >RIV/00064165:_____/22:10448753 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/22:10448753

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Naz1VBlggm" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=Naz1VBlggm</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.ekir.2022.06.010" target="_blank" >10.1016/j.ekir.2022.06.010</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey

Popis výsledku v původním jazyce

Focal segmental glomerulosclerosis (FSGS) is a histopathologic pattern of podocyte injury with several underlying etiologies and is characterized by segmental scarring that involves part of the glomerulus and a subset of glomeruli sampled on biopsy. In adults, nephrotic syndrome (NS) is often characteristic of primary (or idiopathic) FSGS. In children, steroid-resistantnephrotic syndrome (SRNS) is an indication for kidney biopsy and most commonly associated with FSGS histologically. Available treatments do not always produce complete remission, and patients who do not achieve remission often progress to chronic kidney failure. FSGS classification (primary, secondary, genetic, or undetermined cause) and patient-specific factors are used to individualize patient treatment in terms of medications used, dosing, and length of treatment. International guidelines are available to help nephrologists develop management strategies for patients with FSGS or SRNS, but the extent to which nephrologists agree with and may apply this guidance is unknown. The Delphi FSGS and IgA Nephropathy Experts (DEFINE): Physicians study aimed to find consensus on pathophysiology, diagnosis, monitoring, and management of FSGS and IgA nephropathy among nephrologists from Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States. In this 2-round online Delphi survey, agreement with 22 statements about FSGS/SRNS was scored by adult and pediatric nephrologists using a 1 to 9 Likert scale (9 = strongly agree). Moderate versus high consensus were defined as 75% to 89% versus &gt;=90% of participants scoring 7 to 9 on the Likert scale, respectively. Between November 2020 and April 2021, 207 nephrologists completed round 1, and 158 (76%) nephrologists completed round 2 (Figure S1, Tables S1-S4). Methods and participant characteristics are detailed in the Supplementary Materials.

Název v anglickém jazyce

Diagnosis and Treatment of Patients With Focal Segmental Glomerulosclerosis/Steroid-Resistant Nephrotic Syndrome: A Delphi Survey

Popis výsledku anglicky

Focal segmental glomerulosclerosis (FSGS) is a histopathologic pattern of podocyte injury with several underlying etiologies and is characterized by segmental scarring that involves part of the glomerulus and a subset of glomeruli sampled on biopsy. In adults, nephrotic syndrome (NS) is often characteristic of primary (or idiopathic) FSGS. In children, steroid-resistantnephrotic syndrome (SRNS) is an indication for kidney biopsy and most commonly associated with FSGS histologically. Available treatments do not always produce complete remission, and patients who do not achieve remission often progress to chronic kidney failure. FSGS classification (primary, secondary, genetic, or undetermined cause) and patient-specific factors are used to individualize patient treatment in terms of medications used, dosing, and length of treatment. International guidelines are available to help nephrologists develop management strategies for patients with FSGS or SRNS, but the extent to which nephrologists agree with and may apply this guidance is unknown. The Delphi FSGS and IgA Nephropathy Experts (DEFINE): Physicians study aimed to find consensus on pathophysiology, diagnosis, monitoring, and management of FSGS and IgA nephropathy among nephrologists from Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States. In this 2-round online Delphi survey, agreement with 22 statements about FSGS/SRNS was scored by adult and pediatric nephrologists using a 1 to 9 Likert scale (9 = strongly agree). Moderate versus high consensus were defined as 75% to 89% versus &gt;=90% of participants scoring 7 to 9 on the Likert scale, respectively. Between November 2020 and April 2021, 207 nephrologists completed round 1, and 158 (76%) nephrologists completed round 2 (Figure S1, Tables S1-S4). Methods and participant characteristics are detailed in the Supplementary Materials.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2022

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Kidney International Reports

ISSN

2468-0249

e-ISSN

2468-0249

Svazek periodika

7

Číslo periodika v rámci svazku

9

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

5

Strana od-do

2081-2085

Kód UT WoS článku

000863107700017

EID výsledku v databázi Scopus

2-s2.0-85134342309